









Markets
/
Stocks
/
nasdaq-ebs
/

Emergent BioSolutions Inc

EBS

7.940USD

+0.150+1.93%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

426.38MMarket Cap

3.06P/E TTM



Emergent BioSolutions Inc

7.940

+0.150+1.93%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

95 / 175

Overall Ranking

251 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Hold

Current Rating

13.500

Target Price

+73.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Overvalued

The company’s latest PE is 2.98, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 39.60M shares, decreasing 17.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.58M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.03, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 140.90M, representing a year-over-year decrease of 44.68%, while its net profit experienced a year-over-year decrease of 95.76%.

Score

Industry at a Glance

Previous score

7.03

Change



Financials

6.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.83

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.44

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 2.92, which is -6.47% below the recent high of 2.73 and 174.60% above the recent low of -2.18.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 6.67, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Emergent BioSolutions Inc is 13.50, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Hold

Current Rating

13.500

Target Price

+73.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Emergent BioSolutions Inc

EBS

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.49, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 9.15 and the support level at 6.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.154

Neutral

RSI(14)

48.546

Neutral

STOCH(KDJ)(9,3,3)

44.674

Neutral

ATR(14)

0.386

High Vlolatility

CCI(14)

-19.286

Neutral

Williams %R

58.120

Sell

TRIX(12,20)

-0.107

Sell

StochRSI(14)

50.915

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

7.940

Buy

MA10

7.930

Buy

MA20

8.236

Sell

MA50

7.760

Buy

MA100

6.995

Buy

MA200

7.374

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 73.05%, representing a quarter-over-quarter increase of 3.68%. The largest institutional shareholder is The Vanguard, holding a total of 3.58M shares, representing 6.72% of shares outstanding, with 13.97% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

1.58M

-3.71%

The Vanguard Group, Inc.

Star Investors

3.21M

+0.42%

American Century Investment Management, Inc.

2.30M

+7.48%

Dimensional Fund Advisors, L.P.

1.60M

+44.62%

State Street Global Advisors (US)

1.71M

-12.88%

Oak Hill Advisors, L.P.

1.11M

Palisade Capital Management, LLC

1.14M

+21.61%

Marshall Wace LLP

1.16M

-12.85%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.13, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 2.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.